A newly developed treatment for gastric cancer by a group of Korean researchers has been attracting international attention after proving that the procedure can reduce the likelihood of tumors recurring in the wake of a gastrectomy, or the partial or full surgical removal of the stomach.
Patients who follow-up on surgery by injecting the XELOX regimen, a combination of the two chemotherapeutic agents capecitabine and oxaliplatin, have a greater chance of recovering from operable gastric cancer, according to the new study by Dr. Bang Yung-jue of Seoul National University.
The findings of the study were presented at the American Society of Clinical Oncology's annual meeting on Tuesday. The study randomly administered the XELOX regimen to cancer patients from a pool of more than 1,000 people. It then compared the progress of those who received the treatment with those who did not.
Link:http://english.chosun.com/site/data/html_dir/2011/06/09/2011060901141.html
No comments:
Post a Comment